Mark Espeland to Treatment Outcome
This is a "connection" page, showing publications Mark Espeland has written about Treatment Outcome.
Connection Strength
0.598
-
Carmichael OT, Neiberg RH, Dutton GR, Hayden KM, Horton E, Pi-Sunyer FX, Johnson KC, Rapp SR, Spira AP, Espeland MA. Long-term Change in Physiological Markers and Cognitive Performance in Type 2 Diabetes: The Look AHEAD Study. J Clin Endocrinol Metab. 2020 12 01; 105(12).
Score: 0.106
-
Espeland MA, Gaussoin SA, Bahnson J, Vaughan EM, Knowler WC, Simpson FR, Hazuda HP, Johnson KC, Munshi MN, Coday M, Pi-Sunyer X. Impact of an 8-Year Intensive Lifestyle Intervention on an Index of Multimorbidity. J Am Geriatr Soc. 2020 10; 68(10):2249-2256.
Score: 0.104
-
Espeland MA, Shumaker SA, Leng I, Manson JE, Brown CM, LeBlanc ES, Vaughan L, Robinson J, Rapp SR, Goveas JS, Wactawski-Wende J, Stefanick ML, Li W, Resnick SM. Long-term effects on cognitive function of postmenopausal hormone therapy prescribed to women aged 50 to 55 years. JAMA Intern Med. 2013 Aug 12; 173(15):1429-36.
Score: 0.064
-
Espeland MA, Rejeski WJ, West DS, Bray GA, Clark JM, Peters AL, Chen H, Johnson KC, Horton ES, Hazuda HP. Intensive weight loss intervention in older individuals: results from the Action for Health in Diabetes Type 2 diabetes mellitus trial. J Am Geriatr Soc. 2013 Jun; 61(6):912-22.
Score: 0.063
-
Belalcazar LM, Ballantyne CM, Lang W, Haffner SM, Rushing J, Schwenke DC, Pi-Sunyer FX, Tracy RP. Metabolic factors, adipose tissue, and plasminogen activator inhibitor-1 levels in type 2 diabetes: findings from the look AHEAD study. Arterioscler Thromb Vasc Biol. 2011 Jul; 31(7):1689-95.
Score: 0.027
-
Wing RR. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med. 2010 Sep 27; 170(17):1566-75.
Score: 0.026
-
Wing RR, Russell GB, Tate DF, Espeland MA, LaRose JG, Gorin AA, Lewis CE, Jelalian E, Perdue LH, Bahnson J, Polzien K, Ferguson Robichaud E. Examining Heterogeneity of Outcomes in a Weight Gain Prevention Program for Young Adults. Obesity (Silver Spring). 2020 03; 28(3):521-528.
Score: 0.025
-
Biessels GJ, Janssen J, van den Berg E, Zinman B, Espeland MA, Mattheus M, Johansen OE. Rationale and design of the CAROLINA® - cognition substudy: a randomised controlled trial on cognitive outcomes of linagliptin versus glimepiride in patients with type 2 diabetes mellitus. BMC Neurol. 2018 Jan 15; 18(1):7.
Score: 0.022
-
Rapp SR, Luchsinger JA, Baker LD, Blackburn GL, Hazuda HP, Demos-McDermott KE, Jeffery RW, Keller JN, McCaffery JM, Pajewski NM, Evans M, Wadden TA, Arnold SE, Espeland MA. Effect of a Long-Term Intensive Lifestyle Intervention on Cognitive Function: Action for Health in Diabetes Study. J Am Geriatr Soc. 2017 May; 65(5):966-972.
Score: 0.020
-
Wing RR, Tate DF, Espeland MA, Lewis CE, LaRose JG, Gorin AA, Bahnson J, Perdue LH, Hatley KE, Ferguson E, Garcia KR, Lang W. Innovative Self-Regulation Strategies to Reduce Weight Gain in Young Adults: The Study of Novel Approaches to Weight Gain Prevention (SNAP) Randomized Clinical Trial. JAMA Intern Med. 2016 06 01; 176(6):755-62.
Score: 0.019
-
Sink KM, Espeland MA, Castro CM, Church T, Cohen R, Dodson JA, Guralnik J, Hendrie HC, Jennings J, Katula J, Lopez OL, McDermott MM, Pahor M, Reid KF, Rushing J, Verghese J, Rapp S, Williamson JD. Effect of a 24-Month Physical Activity Intervention vs Health Education on Cognitive Outcomes in Sedentary Older Adults: The LIFE Randomized Trial. JAMA. 2015 Aug 25; 314(8):781-90.
Score: 0.018
-
Marx N, Rosenstock J, Kahn SE, Zinman B, Kastelein JJ, Lachin JM, Espeland MA, Bluhmki E, Mattheus M, Ryckaert B, Patel S, Johansen OE, Woerle HJ. Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®). Diab Vasc Dis Res. 2015 May; 12(3):164-74.
Score: 0.018
-
Wing RR, Leahey T, Jeffery R, Johnson KC, Hill JO, Coday M, Espeland MA. Do weight loss and adherence cluster within behavioral treatment groups? Obesity (Silver Spring). 2014 Mar; 22(3):638-44.
Score: 0.016
-
Phelan S, Kanaya AM, Subak LL, Hogan PE, Espeland MA, Wing RR, Burgio KL, DiLillo V, Gorin AA, West DS, Brown JS. Weight loss prevents urinary incontinence in women with type 2 diabetes: results from the Look AHEAD trial. J Urol. 2012 Mar; 187(3):939-44.
Score: 0.014
-
Legault C, Jennings JM, Katula JA, Dagenbach D, Gaussoin SA, Sink KM, Rapp SR, Rejeski WJ, Shumaker SA, Espeland MA. Designing clinical trials for assessing the effects of cognitive training and physical activity interventions on cognitive outcomes: the Seniors Health and Activity Research Program Pilot (SHARP-P) study, a randomized controlled trial. BMC Geriatr. 2011 May 26; 11:27.
Score: 0.014
-
Williamson JD, Espeland M, Kritchevsky SB, Newman AB, King AC, Pahor M, Guralnik JM, Pruitt LA, Miller ME. Changes in cognitive function in a randomized trial of physical activity: results of the lifestyle interventions and independence for elders pilot study. J Gerontol A Biol Sci Med Sci. 2009 Jun; 64(6):688-94.
Score: 0.012
-
Chambers MS, Fleming TJ, Toth BB, Lemon JC, Craven TE, Bouwsma OJ, Garden AS, Espeland MA, Keene HJ, Martin JW, Sipos T. Erratum to "Clinical evaluation of the intraoral fluoride releasing system in radiation-induced xerostomic subjects. Part 2: Phase I study". Oral Oncol. 2007 Jan; 43(1):98-105.
Score: 0.010
-
Niparko JK, Wang NY, Rauch SD, Russell GB, Espeland MA, Pierce JJ, Bowditch S, Masuda A, Gulya AJ, Gantz BJ, Hughes GB, Brookhouser PE, Hannley MT, Telian SA, Harris JP. Serial audiometry in a clinical trial of AIED treatment. Otol Neurotol. 2005 Sep; 26(5):908-17.
Score: 0.009
-
Resnick SM, Coker LH, Maki PM, Rapp SR, Espeland MA, Shumaker SA. The Women's Health Initiative Study of Cognitive Aging (WHISCA): a randomized clinical trial of the effects of hormone therapy on age-associated cognitive decline. Clin Trials. 2004; 1(5):440-50.
Score: 0.008